VXRT - Vaxart EV/EBITDA Multiple

Corporate company logo of Vaxart Inc. (VXRT)

Vaxart, Inc. (VXRT) is implementing automated data analysis and robotic screeners to accelerate clinical testing. The growth in government orders for convenient vaccines is supported by geopolitical tensions and the threat of epidemics. This price chart, where the EV/EBITDA ratio equals , confirms the value of an innovative workforce that attracts leading scientists through stock options and the status of being creators of a new biotech era.

VXRT Vaxart Corp: Business Value to Operating Income Before Depreciation in the range 07/04/2022 - 11/12/2026
Original product of Vaxart Inc.

Selecting reliable equity assets requires analyzing business value relative to its operating profit before depreciation and interest. This indicator compares a company's total market value with its EBITDA, allowing for an assessment of the efficiency of debt and tax management. For Vaxart, Inc. (VXRT), which requires capital due to the development risks of tablet vaccines, the company's EV/EBITDA multiple serves as a dynamic indicator of whether the asset is overvalued or undervalued.

Competitors of Vaxart, Inc.

Gilead Sciences Inc - Enterprise Value to EBITDA Ratio|Cidara - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Novavax, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio curevac.com CVAC|Valneva (VALN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Vir Biotechnology Inc - Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio SIGA|EV/EBITDA Multiple Emergent Bio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Atea Pharmaceuticals (AVIR)|Total Company Value to Operating Income Before Depreciation Ratio invivyd.com|Enanta Pharmaceuticals, Inc. - Enterprise Value to EBITDA Ratio|Inovio Pharmaceuticals, Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|HilleVax Corp - EV/EBITDA Multiple|KLRS - EV/EBITDA Multiple|DYAI (dyadic.com) - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation NNVC|TLPH (Talphera) - EV/EBITDA Multiple|EV/EBITDA Multiple Cocrystal Pharma Inc|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Traws Pharma, Inc. (TRAW)|DWTX (dwtx.com) - Business Value to Operating Income Before Depreciation|Qualigen Therapeutics - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio ALVR (AlloVir Inc)|VBIV: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation VIRI (Virios Therapeutics)